QuadVantage Technology
About this raise
QuadVantage Technology is raising funds on Dealmaker Securities. The company is transforming ACL reconstruction surgery with its QuadVantage Autograft System. The QuadVantage Quadriceps Autograft System makes the harvesting of Quadriceps tendon easier, more precise, less painful, and less traumatic. QuadVantage’s technology is clinically tested and has received FDA approvals. The technology helps to eliminate guesswork, leaves only a small scar, and costs less compared to competitors. Thomas Gutierrez founded QuadVantage Technology in October 2018. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5,000,000. The campaign proceeds will be used for growth and expansion.
Investment Overview
Invested $295,750 :
Deal Terms
Company & Team
Company
- Year Founded
- 2018
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Low
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $450,000
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
04/10/2023 | DealMaker Securities | $9,800,000 | $295,750 | Equity - Preferred | Funded | RegCF |